Date: June 25, 2025
Time: 8:00 AM (PT), 11:00 AM (ET)
The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a distinguished expert in flow cytometry, will guide participants through the critical aspects of Next Generation Flow™ beyond mere MRD status determination.
Key topics will include:
- The importance of analyzing all cell populations within a sample to avoid incomplete assessments
- Potential pitfalls of sample hemodilution.
- The sensitivity of Next Generation Flow™ assays and the rationale for maintaining a detection threshold of 10-5.
- The influence of monoclonal therapies on data analysis, with a special focus on CD38 expression.
- Description of Next Generation Flow™ cytometry and its advantages in screening of PIDs.
Dr. Flores-Montero will also provide practical examples using BD Infinicyt™ software, demonstrating the application of Next Generation Flow™ in real-world scenarios.
Learning Objectives
- Understand the importance of analyzing all cell populations within a sample to avoid incomplete assessments and ensure accurate Minimal Residual Disease (MRD) analysis in Multiple Myeloma (MM).
- Recognize the potential pitfalls of sample hemodilution and the influence of monoclonal therapies on data analysis, with a special focus on CD38 expression, to enhance the reliability of Next Generation Flow™ assays.
- Learn the rationale for maintaining a detection threshold of 10^-5 and the advantages of using dual-tube approaches over
Webinars will be available for unlimited on-demand viewing after live event.